BlossomHill Posts $8.75 Q2 Loss Per Share in First Report Since IPO
BLSM sits 70% above its 52-week low of $15.6.
Summary
BlossomHill reported a Q2 loss of $8.75 per share, its first quarterly result since the August IPO. The company's Q2 net loss was $23.8 million, reflecting heavy R&D spending on BH-30643, which recently showed a 45% objective response rate in Phase 1/2 SOLARA data. BlossomHill raised $150 million at $16.00 per share in its IPO, and the stock now trades near its 52-week high of $27.80, suggesting investors are focused on clinical progress rather than near-term profitability. The company has raised $168.3 million in total from the IPO, and its cash runway is expected to fund operations into 2Q 2028. The loss is in line with expectations for a clinical-stage biotech, but the magnitude underscores the cash burn rate.
At the time of this announcement, BLSM was trading at $26.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $821.9M. The 52-week trading range was $15.60 to $27.80. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.